SuperworthPROCEPT BioRobotics profit margin PRCT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.
- Net margin, 12 months
- −32.5%
- Operating margin, 12 months
- −33.9%
- Net margin on a year earlier
- −1.9 pts
- Peer median
- 7.7%
Over the twelve months to Jun 30, 2026, PROCEPT BioRobotics kept −32.5% of its revenue as net profit, with an operating margin of −33.9% and a gross margin of 64.2%.
The median for 10 medical instruments and supplies stocks of a similar size is 7.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −31.0% | −33.7% | 63.7% |
| FY2024 | −40.7% | −43.0% | 61.1% |
| FY2023 | −77.8% | −80.2% | 52.2% |
| FY2022 | n/a | n/a | 49.4% |
| FY2021 | n/a | n/a | 46.0% |
| FY2020 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −32.5% | −1.9 pts | −33.9% | |
| Q1 FY26 | −31.8% | +4.4 pts | −33.9% | |
| Q4 FY25 | −31.0% | +9.7 pts | −33.7% | |
| Q3 FY25 | −28.2% | +21.9 pts | −30.9% | |
| Q2 FY25 | −30.6% | +28.1 pts | −33.4% | |
| Q1 FY25 | −36.2% | +29.9 pts | −38.7% | |
| Q4 FY24 | −40.7% | +37.0 pts | −43.0% | |
| Q3 FY24 | −50.1% | +41.5 pts | −53.3% | |
| Q2 FY24 | −58.7% | n/a | −62.1% | |
| Q1 FY24 | −66.1% | n/a | −69.4% | |
| Q4 FY23 | −77.8% | n/a | −80.2% | |
| Q3 FY23 | −91.6% | n/a | −89.9% |
Against its peers
Companies in Medical - Instruments & Supplies nearest PROCEPT BioRobotics' size, closest first, today.
| Company | Profit margin |
|---|---|
| PRCTPROCEPT BioRobotics | −32.5% |
| STAAStaar Surgical | 1.1% |
| IRMDIradimed | 26.7% |
| BVSBioventus | 9.4% |
| CDRECadre | 5.3% |
| EYENational Vision | 2.5% |
| MOVMovado | 6.0% |
| LMATLemaitre Vascular | 25.0% |
| INSPInspire Medical Systems | 15.0% |
| UFPTUFP Technologies | 11.4% |
| MDXGMimedx | 1.8% |
| Peer median | 7.7% |
Where PROCEPT BioRobotics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on PROCEPT BioRobotics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.